The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images Novo Nordisk on Monday said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company’s sales … Read more
The Hims logo arranged on a smartphone in New York, US, on Wednesday, Feb. 12, 2025. Bloomberg | Bloomberg | Getty Images Hims & Hers Health announced Tuesday it will acquire European telehealth platform Zava in its push to expand globally. “We’re excited to take this moment to really accelerate both the European expansion, but … Read more
Shares of Hims & Hers Health fell in extended trading on Monday after the company reported first-quarter earnings that beat analysts’ expectations but offered weaker-than-expected guidance. Here’s how the company did based on average analysts’ estimates compiled by LSEG: Earnings per share: 20 cents vs. 12 cents Revenue: $586 million vs. $538 million Revenue at … Read more
Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Courtesy: Hims & Hers Hims & Hers Health on Monday announced Nader Kabbani, a former Amazon executive who helped … Read more
The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images Novo Nordisk on Tuesday said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and … Read more
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk scored a huge legal victory that … Read more
The Hims app arranged on a smartphone in New York on Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images Hims & Hers Health shares rose more than 5% on Tuesday after the company announced patients can access Eli Lilly‘s weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection … Read more
This week was supposed to mark the end of compounding pharmacies making copycat versions of Eli Lilly‘s weight-loss drug Zepbound and its diabetes drug Mounjaro. Online, it doesn’t look like much has changed. Popular websites like Amble, EllieMD, Willow and Mochi Health are all still advertising versions of tirzepatide, the active ingredient in Zepbound. Some, … Read more
Shares of Hims & Hers Health closed down 22% on Tuesday, a day after the telehealth company released fourth-quarter results that disappointed on gross margin and sparked concerns about the future of its weight loss business. Hims & Hers reported $481 million in revenue for the quarter, up 95% from $246.6 million during the same … Read more
Hims & Hers Health shares plunged 18% in extended trading on Monday after investors looked past better-than-expected revenue and earnings and focused instead on the disappointing gross margin. Here’s how the company did, compared to analysts’ consensus estimates from LSEG: Earnings per share: 11 cents vs. 10 cents expected Revenue: $481 million vs. $470 million expected … Read more